Randomized trial of botulinum toxin to prevent pes cavus progression in pediatric charcot-marie-tooth disease type 1A: Burns J et al.

Abstract: Pes cavus in Charcot–Marie–Tooth disease type1A (CMT1A) is thought to be due to muscle imbalance of the lower leg. Botulinum toxin type A (BoNT-A) can modify foot deformity in other conditions of muscle imbalance. ….

Musscle Nerve  42: 262–267, 2010
Authors
JOSHUA BURNS, PhD, 1,2
ADAM SCHEINBERG, MMed, 3,4
MONIQUE M. RYAN, MMed, 5
KRISTY J. ROSE, MHSc, 2
and ROBERT A. OUVRIER, MD, 2
Author Details
1 Faculty of Health Sciences, University of Sydney, Sydney, New South Wales, Australia 
2 Institute for Neuroscience and Muscle Research, Children’s Hospital at Westmead, Locked Bag 4001, Sydney,New South Wales 2145, Australia 
3 Department of Rehabilitation, The Children’s Hospital at Westmead, Sydney, New South Wales, Australia 
4  Victorian Paediatric Rehabilitation Service, Victoria, Australia 
5 Children’s Neuroscience Centre, Royal Children’s Hospital/Murdoch Children’s Research Institute/Department of Paediatrics,Faculty of Medicine, University of Melbourne, Victoria, Australia

Please click here!